Javier O Morales-Ramirez

4.3k total citations · 1 hit paper
13 papers, 1.9k citations indexed

About

Javier O Morales-Ramirez is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Javier O Morales-Ramirez has authored 13 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 11 papers in Virology and 4 papers in Emergency Medicine. Recurrent topics in Javier O Morales-Ramirez's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (8 papers). Javier O Morales-Ramirez is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (8 papers). Javier O Morales-Ramirez collaborates with scholars based in United States, Thailand and Peru. Javier O Morales-Ramirez's co-authors include Dominic Labriola, Douglas J. Manion, Nancy Ruíz, Richard Stryker, Daniel J. Skiest, James Stanford, Philip C. Johnson, Schlomo Staszewski, Anita Rachlis and Karen T. Tashima and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and AIDS.

In The Last Decade

Javier O Morales-Ramirez

13 papers receiving 1.9k citations

Hit Papers

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus ... 1999 2026 2008 2017 1999 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
    1999 788 citations Schlomo Staszewski, Javier O Morales-Ramirez et al. New England Journal of Medicine profile →

Peers

Javier O Morales-Ramirez
Brian Woodfall United States
Erin Quirk United States
Franco Maggiolo Italy
Martin S. Rhee United States
Clare Brennan United States
Cindy Vavro United States
Susan L. Ford United States
Marshall W. Fordyce United States
Johan Vingerhoets United States
Cynthia Brinson United States
Brian Woodfall United States
Javier O Morales-Ramirez
Citations per year, relative to Javier O Morales-Ramirez Javier O Morales-Ramirez (= 1×) peers Brian Woodfall

Countries citing papers authored by Javier O Morales-Ramirez

Since Specialization
Citations

This map shows the geographic impact of Javier O Morales-Ramirez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier O Morales-Ramirez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier O Morales-Ramirez more than expected).

Fields of papers citing papers by Javier O Morales-Ramirez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier O Morales-Ramirez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier O Morales-Ramirez. The network helps show where Javier O Morales-Ramirez may publish in the future.

Co-authorship network of co-authors of Javier O Morales-Ramirez

This figure shows the co-authorship network connecting the top 25 collaborators of Javier O Morales-Ramirez. A scholar is included among the top collaborators of Javier O Morales-Ramirez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier O Morales-Ramirez. Javier O Morales-Ramirez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Russell, Kevin L., Richard Rupp, Javier O Morales-Ramirez, et al.. (2022). A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults. Human Vaccines & Immunotherapeutics. 18(5). 2046960–2046960. 20 indexed citations
2.
3.
4.
Thompson, Melanie, Javier O Morales-Ramirez, Cheryl McDonald, et al.. (2015). Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
5.
Gotuzzo, Eduardo, Martin Markowitz, Winai Ratanasuwan, et al.. (2012). Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 61(1). 73–77. 19 indexed citations
6.
Wilkin, Aimee, Anton Pozniak, Javier O Morales-Ramirez, et al.. (2011). Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial. AIDS Research and Human Retroviruses. 28(5). 437–446. 45 indexed citations
7.
Pozniak, Anton, Javier O Morales-Ramirez, Elly Katabira, et al.. (2009). Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 24(1). 55–65. 89 indexed citations
8.
DeJesus, Edwin, Benjamin Young, Javier O Morales-Ramirez, et al.. (2009). Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(2). 163–174. 108 indexed citations
9.
Markowitz, Martin, Bach‐Yen Nguyen, Eduardo Gotuzzo, et al.. (2009). Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 52(3). 350–356. 94 indexed citations
10.
Morales-Ramirez, Javier O, Stefan Schneider, Albrecht Stoehr, et al.. (2009). Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naïve, HIV-1-infected ARTEMIS patients …. 4 indexed citations
11.
Markowitz, Martin, Bach‐Yen Nguyen, Eduardo Gotuzzo, et al.. (2007). Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(2). 125–133. 317 indexed citations
12.
Markowitz, Martin, Javier O Morales-Ramirez, Bach‐Yen Nguyen, et al.. (2006). Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 509–515. 293 indexed citations
13.
Staszewski, Schlomo, Javier O Morales-Ramirez, Karen T. Tashima, et al.. (1999). Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. New England Journal of Medicine. 341(25). 1865–1873. 788 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian Woodfall Breakdown of academic impact, for papers by Erin Quirk Breakdown of academic impact, for papers by Franco Maggiolo Breakdown of academic impact, for papers by Martin S. Rhee Breakdown of academic impact, for papers by Clare Brennan Breakdown of academic impact, for papers by Cindy Vavro Breakdown of academic impact, for papers by Susan L. Ford Breakdown of academic impact, for papers by Marshall W. Fordyce Breakdown of academic impact, for papers by Johan Vingerhoets Breakdown of academic impact, for papers by Cynthia Brinson
Rankless by CCL
2026